$GILD

Mercier Johanna sold $390K of GILD

Mercier Johanna (Chief Comm & Corp Aff Officer) sold 3,000 shares of GILEAD SCIENCES, INC. (GILD) at $129.92 ($0.39M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mercier Johanna
Published Jul 16, 2026, 8:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GILD
Neutral
high confidence
Mentioned
$GILD
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GILDNeutralLow
01

Why it matters

The disclosure provides transparency on an officer’s scheduled open-market sale but does not introduce new company fundamentals.

02

Market read

Traders may treat this as routine insider activity with minimal impact unless paired with other new catalysts.

03

What to watch

The article does not state whether the sale was part of a larger scheduled program, nor does it provide context on total holdings changes beyond the post-transaction share count.

Relevance 3/10Novelty 2/10Timing: Filed after-hours on 2026-07-16, covering a sale dated 2026-07-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Gilead Sciences, Inc.

Company-level read

Ticker impact

$GILDNeutralHigh confidence
Context

SEC Form 4 shows Gilead officer Mercier Johanna sold 3,000 shares on 2026-07-15 for about $389,758 under a 10b5-1 plan.

Expected impact

Likely negligible near-term price impact; any effect would be sentiment-only and small.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operational, financial, or regulatory information.

Market effects

No sector read-through; this is company-specific insider transaction data without new guidance or events.

None.

None.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so traders may watch for follow-on filings or changes in selling pace.

Key entities

  • Gilead Sciences, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Mercier Johanna

    Chief Comm & Corp Aff Officer who sold shares.

  • 10b5-1 plan

    Pre-arranged plan cited as Yes, indicating the sale was scheduled.

Related articles

$GILDMed

Weekly HIV Pill Held Viral Suppression as Well as Daily Therapy in Phase 3 Trial

Phase 3 ISLEND-1 results in the New England Journal of Medicine found a once-weekly tablet of islatravir 2 mg plus lenacapavir 300 mg was noninferior to once-daily bictegravir, emtricitabine, and tenofovir alafenamide for maintaining HIV viral suppression at 48 weeks in 607 adults already suppressed for at least 6 months. None on weekly therapy had HIV-1 RNA ≥50 copies/mL vs 0.3% on daily. Serious adverse events were 5.3% vs 4.6%.

$GILDMedAI 8/10

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences (GILD) reported Q2 2026 non-GAAP loss per share of $6.75 and revenue of $7.8B, both above consensus. Management raised 2026 product sales guidance excluding Veklury to $29.8B-$30.1B and lifted HIV sales growth outlook to 9%-10%. CEO cited HIV and PrEP strength, Trodelvy growth, and ongoing anito-cel launch prep.

$MRKMed

MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data

Merck & Co (MSD) and Gilead Sciences ended the Phase III KEYNOTE-D46/EVOKE-03 trial in frontline PD-L1-expressing NSCLC after an external data monitoring committee projected the Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) would not significantly improve overall survival versus Keytruda alone. Trodelvy-Keytruda showed nonsignificant PFS benefit and no new safety issues. Trodelvy Q2 2026 sales rose 26% to $457m.

$GILDMed

GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure

Gilead Sciences (GILD) reported Q2 CY2026 revenue of $7.80 billion, up 10.2% year over year, and a non-GAAP loss of $6.75 per share. Full-year revenue guidance was $30.25 billion at the midpoint, 0.6% below analysts’ estimates. Management cited HIV franchise strength, including Biktarvy and PrEP, plus Trodelvy growth, while noting margin pressure from acquisition-related R&D costs.